GAO “High-Risk List” Urges Enhanced FDA Oversight Of Medical Products
This article was originally published in The Pink Sheet Daily
Executive Summary
Recent initiatives hold promise, but “effective implementation” is required to make “meaningful differences,” oversight office says.